Predictors of treatment resistance in patients with schizophrenia: A population-based cohort study

The Lancet Psychiatry

Volumn 3, Issue 4, 2016, Pages 358-366

  Wimberley, Theresa ^a   Støvring, Henrik ^a   Sørensen, Holger J ^a,b   Horsdal, Henriette T ^a   MacCabe, James H ^c   Gasse, Christiane ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PARANOIA; PERSONALITY DISORDER; POPULATION RESEARCH; SCHIZOPHRENIA; URBAN AREA; YOUNG ADULT; ADOLESCENT; COHORT ANALYSIS; DENMARK; REGISTER; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COHORT STUDIES; DENMARK; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959113311     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(15)00575-1     Document Type: Article

References (38)

1. Barnes TR Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011, 25:567-620. Schizophrenia Consensus Group of British Association for Psychopharmacology.
2. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Updated edition. National clinical guideline number 82 2009, National Collaborating Centre for Mental Health, British Psychological Society, Leicester.
3. Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv 2014, 65:186-192.
4. Tan CH, Shinfuku N, Sim K Psychotropic prescription practices in east Asia: looking back and peering ahead. Curr Opin Psychiatry 2008, 21:645-650.
5. Nielsen J, Roge R, Schjerning O, Sorensen HJ, Taylor D Geographical and temporal variations in clozapine prescription for schizophrenia. Eur Neuropsychopharmacol 2012, 22:818-824.
6. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382:951-962.
7. Novick D, Haro JM, Suarez D, Vieta E, Naber D Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res 2009, 108:223-230.
8. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012, 201:481-485.
9. Gee S, Vergunst F, Howes O, Taylor D Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014, 130:16-24.
10. Kane JM, Correll CU Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci 2010, 12:345-357.
11. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 2014, 29:63-76.
12. Harris MG, Henry LP, Harrigan SM, et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res 2005, 79:85-93.
13. Carbon M, Correll CU Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci 2014, 16:505-524.
14. Agerbo E, Byrne M, Eaton WW, Mortensen PB Marital and labor market status in the long run in schizophrenia. Arch Gen Psychiatry 2004, 61:28-33.
15. Laursen TM, Munk-Olsen T, Nordentoft M, Bo MP A comparison of selected risk factors for unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia from a Danish population-based cohort. J Clin Psychiatry 2007, 68:1673-1681.
16. Pedersen CB, Mortensen PB Family history, place and season of birth as risk factors for schizophrenia in Denmark: a replication and reanalysis. Br J Psychiatry 2001, 179:46-52.
17. Thorup A, Waltoft BL, Pedersen CB, Mortensen PB, Nordentoft M Young males have a higher risk of developing schizophrenia: a Danish register study. Psychol Med 2007, 37:479-484.
18. Huber CG, Naber D, Lambert M Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors. Expert Opin Pharmacother 2008, 9:2027-2038.
19. Nielsen PR, Laursen TM, Mortensen PB Association between parental hospital-treated infection and the risk of schizophrenia in adolescence and early adulthood. Schizophr Bull 2013, 39:230-237.
20. Pedersen CB The Danish Civil Registration System. Scand J Public Health 2011, 39(7 suppl):22-25.
21. Mors O, Perto GP, Mortensen PB The Danish Psychiatric Central Research Register. Scand J Public Health 2011, 39(7 suppl):54-57.
22. Lynge E, Sandegaard JL, Rebolj M The Danish national patient register. Scand J Public Health 2011, 39(7 suppl):30-33.
23. Kildemoes HW, Sorensen HT, Hallas J The Danish national prescription registry. Scand J Public Health 2011, 39(7 suppl):38-41.
24. Jensen VM, Rasmussen AW Danish education registers. Scand J Public Health 2011, 39(7 suppl):91-94.
25. Kyvsgaard B The criminal career 1998, Cambridge University Press, Cambridge.
26. Kane J, Honigfeld G, Singer J, Meltzer H Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789-796.
27. Glenthøj B, Gerlach J, Licht R, Gulmann N, Jørgensen OS Treatment with antipsychotics. Guidelines 1998, Danish Psychiatric Association, Denmark, (in Danish).
28. Damkier P, Larsen JT, Rasmussen S, Nielsen B, Hansen VH Clinical guidelines for treatment with antipsychotics 2007, Odense University Hospital, Denmark, (in Danish).
29. Fink-Jensen A, Rasmussen I, Viuff AG, et al. Treatment guidelines including recommendations for medical treatment of psychoses in adults 2014, The Council for Utilization of Expensive Drugs, Denmark, (in Danish).
30. Suzuki T, Remington G, Mulsant BH, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res 2012, 197:1-6.
31. Pedersen CB, Mors O, Bertelsen A, et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry 2014, 71:573-581.
32. Baandrup L, Allerup P, Nordentoft M, Lublin H, Glenthoj BY Exploring regional variation in antipsychotic coprescribing practice: a Danish questionnaire survey. J Clin Psychiatry 2010, 71:1457-1464.
33. Manuel JI, Essock SM, Wu Y, Pangilinan M, Stroup S Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees. Psychiatr Serv 2012, 63:1146-1149.
34. Vassos E, Pedersen CB, Murray RM, Collier DA, Lewis CM Meta-analysis of the association of urbanicity with schizophrenia. Schizophr Bull 2012, 38:1118-1123.
35. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 2012, 169:1203-1210.
36. Selten JP, van der Ven E, Rutten BP, Cantor-Graae E The social defeat hypothesis of schizophrenia: an update. Schizophr Bull 2013, 39:1180-1186.
37. Schneider C, Papachristou E, Wimberley T, et al. Clozapine use in childhood and adolescent schizophrenia: a nationwide population-based study. Eur Neuropsychopharmacol 2015, 25:857-863.
38. Wheeler AJ, Feetam CL, Harrison J Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom. Clin Drug Investig 2014, 34:203-211.